Correction: Efficacy of Intravenous Immunoglobulin for Systemic Manifestations of Dermatomyositis Beyond Muscular and Cutaneous: Sub‑analysis of the ProDERM Study

Correction to: Rheumatol Ther (2025) 12:855–871

https://doi.org/10.1007/s40744-025-00775-5

In the sentence beginning ‘With IVIg, the proportions of patients…’ in the Results section of the Abstract of this article, the values in the text ‘arthralgia (68.1 to 0.0%; P < 0.001), and fatigue (68.1 to 3.3%; P = 0.008)’ should have read ‘arthralgia (68.1 to 40.0%; P < 0.001), and fatigue (68.1 to 53.3%; P = 0.008)’. The incorrect and the correct text version is provided below.

Incorrect version:

With IVIg, the proportions of patients with arthritis (36.2 to 17.8%; P = 0.01), arthralgia (68.1 to 0.0%; P < 0.001), and fatigue (68.1 to 3.3%; P = 0.008) decreased from baseline to week 16.

Corrected version:

With IVIg, the proportions of patients with arthritis (36.2 to 17.8%; P = 0.01), arthralgia (68.1 to 40.0%; P < 0.001), and fatigue (68.1 to 53.3%; P = 0.008) decreased from baseline to week 16.

The original article has been corrected.